NCT06739473 Total-body Glucose Utilization in Obesity
| NCT ID | NCT06739473 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Turku University Hospital |
| Condition | Obesity and Overweight |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2023-01-25 |
| Primary Completion | 2024-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 60 participants in total. It began in 2023-01-25 with a primary completion date of 2024-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
There are three goals for this study. One is to investigate how different emotions and exposure to cold affect blood flow in the body. The second aim is to study how insulin affects blood flow and tissue glucose uptake, and to study whether this effect is altered in obesity. Last, the study focuses on establishing the lowest dose of a PET radiotracer, oxygen-15 labelled water, that can be used in clinical studies with a new whole-body PET scanner.
Eligibility Criteria
Inclusion Criteria: 1. Age 20-60 years 2. BMI either 18.5-25 kg/m2 or above 30 kg/m2 3. Use of hormonal contraception for women in child bearing age Exclusion Criteria: 1. In the lean group history of obesity or type 2 diabetes 2. In the group with obesity: current or previous use of GLP-1-agonists or insulin 3. History of eating disorders 4. Smoking, use of narcotics, excessive use of alcohol 5. Previous participation in PET studies 6. Previous significant exposure to radiation 7. Claustrophobia 8. Active plans for concieving (both sexes) 9. Any other condition that in the opinion of the investigator could create a hazard to the subject safety, endanger the study procedures or interfere with the interpretation of study results
Contact & Investigator
Lauri Nummenmaa, Professor
PRINCIPAL INVESTIGATOR
University of Turku
Frequently Asked Questions
Who can join the NCT06739473 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 60 Years, studying Obesity and Overweight. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06739473 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06739473 currently recruiting?
Yes, NCT06739473 is actively recruiting participants. Contact the research team at aehyyp@utu.fi for enrollment information.
Where is the NCT06739473 trial being conducted?
This trial is being conducted at Turku, Finland.
Who is sponsoring the NCT06739473 clinical trial?
NCT06739473 is sponsored by Turku University Hospital. The principal investigator is Lauri Nummenmaa, Professor at University of Turku. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.